Chardan analyst Geulah Livshits raised the firm’s price target on Crispr Therapeutics to $166 from $110 and keeps a Buy rating on the shares following the latest data on ex vivo CRISPR therapy CTX001. The CTX001 update is an “important advance,” demonstrating fetal hemoglobin levels that are consistent across a growing number of patients, maintained greater than one year of follow-up, and translate to meaningful clinical metrics, Livshits tells investors in a research note. As a results, the analyst increased the probability of success from 40% to 65% in transfusion-dependent beta thalassemia and to 60% in sickle cell disease.
previous post
next post